TUBERCULOSIS AND AIDS

结核病和艾滋病

• 批准号: 6115234
• 负责人: JOHN E CONTE
• 金额: $ 5.16万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115234
• 关键词: AIDS; AIDS therapy; HIV infections; blood chemistry; bronchoscopy; clinical research; combination chemotherapy; comorbidity; diagnostic respiratory lavage; dosage; drug screening /evaluation; human subject; human therapy evaluation; isoniazid; microorganism disease chemotherapy; pharmacokinetics; phlebotomy; plasma; pyrazinamide; respiratory disorder chemotherapy; rifamycins; tuberculosis

We will determine and compare the multiple dose intrapulmonary pharmacokinetics and plasma concentrations of isoniazid, rifampin, and pyrazinamide in HIV-infected and uninfected patients who are being treated for pulmonary tuberculosis. The GCRC is critical to this study. Patients will undergo bronchoscopy and bronchoalveolar lavage, blood draws, and serial observations.

我们将确定并比较接受肺结核治疗的HIV和未感染的患者中多种剂量的异尼氏菌，利福平和吡嗪酰胺的多剂量肺内药代动力学和血浆浓度。 GCRC对这项研究至关重要。 患者将进行支气管镜检查，支气管肺泡灌洗，血液抽血和连续观察。